Trial Profile
Phase1/2 study of nab-Paclitaxel + trastuzumab therapy in 2nd line treatment for HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab combined with fluoropyrimidine and platinum.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 18 Sep 2018
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab
- Indications Gastric cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Sep 2018 Status changed from recruiting to discontinued.
- 03 Sep 2014 New trial record